Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

By P. Roberts, C. Der. Oncogene, 2007

2,862 citations recorded by the source corpus.

Subfields: Molecular Biology, Organic Chemistry

View Paper: https://www.semanticscholar.org/paper/28b888dfbc60eaab0612fad78411ba9bba418f27

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. R. Anjum
2. Ping Wee
3. Zhixiang Wang
4. J. Blenis
5. Geou-Yarh Liou
6. Miguel Andrade
7. P. Soares
8. J. Lopes

In Organic Chemistry

1. Geou-Yarh Liou
2. Ping Wee
3. Zhixiang Wang
4. Ji Luo
5. Stephen J. Elledge
6. N. Solimini

Citations in the corpus

• A Directed Protein Interaction Network for Investigating Intracellular Signal Transduction (2011, background): “Mutations in RTKs or in downstream proteins, such as Ras and Raf, lead to abnormal RTK signaling through the ERK pathway, which contributes to the development of disease ( 4 – 6 ).”
• The RSK family of kinases: emerging roles in cellular signalling (2008, background): “jpg" NDATA ITEM> ]> The Ras–mitogen-activated protein kinase (MAPK) pathway is a key signalling pathway that is involved in the regulation of normal cell proliferation, survival, growth and differentiatio”
• Phosphorylation: Implications in Cancer (2017, background): “MAPK cascade get disordered in cancer [17].”
• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies (2023, neutral): “68,69 RAS .”
• The MAPK pathway across different malignancies: A new perspective (2014, background): “Infrequently, 2 mutations can be identified in the RAS/ RAF/MEK/ERK pathway within the same tumor, demonstrating tumoral molecular heterogeneity.(48) The sensitivity of mutation detection depends on the dominant population of cells represented in the tumor sample that is tested and, thus, may not be”
• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways (2017, background): “MEK1 and MEK2 are activated by RAF-1, its only known substrates [201].”
• The mTOR Signalling Pathway in Human Cancer (2012, background): “cytosolic and nuclear substrates leading to regulation of gene expression, cytoskeleton and metabolic remodelling [78,79].”
• Reactive oxygen species in cancer (2010, background): “ovarian cancer, breast cancer, melanoma and leukemia) that the activation of Erk1/2 through ROS increases cell survival, anchorage-independent growth and motility [60, 65, 66].”
• Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction (2009, positive): “This strategy has proven successful for the protein kinase oncogenes BCR-ABL (imatinib/Gleevec), EGFR (gefitinib/Iressa, erlotinib/Tarceva), and HER2 (trastuzumab/Herceptin) (Druker, 2002; Roberts and Der, 2007; Sharma et al., 2007), and efforts toward inhibition of BRAF, MDM2, and the lipid kinase ”
• Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? (2010, neutral): “and the inhibition of downstream effector signallin”